Wilson Disease News and Research

RSS

Acute hepatitis and adenovirus infection among pediatric patients in Alabama

A new study published by the Centers for Disease Control and Prevention (CDC) today, "Acute Hepatitis and Adenovirus Infection Among Children -; Alabama, October 2021–February 2022" provides additional clinical and epidemiologic information from an ongoing investigation involving children in Alabama with hepatitis (inflammation of the liver) of unknown cause.

5 May 2022

New taxonomic classification of non-skeletal rare congenital disorders with impact on bone physiology

Thanks to major progress in the understanding and management of rare congenital diseases and syndromes, many patients with these rare disorders are now living longer lives.

13 Jan 2021

NIH awards $26.56 million grant to create new Framingham Heart Study Brain Aging Program

Since 1976, the Framingham Heart Study (FHS)--the longest running multi-generational epidemiological study in the world--has followed participants for incident dementia.

14 Sep 2020

'A new era of drug discovery’: Company develops drug using AI

For the first time, a company has discovered a drug target and corresponding candidate using artificial intelligence (AI).

26 Sep 2019

Chemist explores link between Alzheimer's and copper protein molecules in brain cells

A University of Houston chemist is exploring the link between copper protein molecules in brain cells and neurodegenerative diseases like Alzheimer's.

17 Sep 2019

Scientists highlight advances and uses of organoids in gastroenterology and hepatology

One of the most exciting advancements in stem cell research has been the development of organoid systems, which are organ-like three-dimensional structures that mimic their corresponding organ in vivo.

4 Jun 2019

Highly efficient bacterial agent could improve treatment of Wilson disease

In the 'Journal of Clinical Investigation', scientists at the Helmholtz Zentrum München describe a small peptide that very efficiently binds excess copper from liver cells. This molecule comes from a bacterium's bag of tricks and could be suitable for treating Wilson disease.

21 Jun 2016

Analysis reveals improved survivorship for acute liver failure patients

More patients hospitalized with acute liver failure - often the result of acetaminophen overdose - are surviving, including those who receive a liver transplant and those who don't, an analysis led by a UT Southwestern Medical Center researcher showed.

5 Apr 2016

Research shows how developing neurons use copper for their various needs

Researchers at Johns Hopkins have used a precision sensor in a chicken embryo to find dramatic differences in the use of copper between developing and fully mature neurons.

17 Feb 2016

Wilson Therapeutics supports BIG WOW event to increase awareness of Wilson's Disease

Wilson Therapeutics AB, a privately-held biopharmaceutical company, today announced its sponsorship of the first annual Big Walk on Wilson's (BIG WOW). The event will take place on September 19, 2015 in sixteen cities across North America to increase awareness of Wilson's Disease and raise funds for the Wilson Disease Association.

17 Jun 2015

Wilson Therapeutics' WTX101-201 Phase 2 clinical study to be presented at EASL annual meeting

Wilson Therapeutics AB, a development stage biopharmaceutical company, today announced that a poster of the company's ongoing Phase 2 clinical trial for WTX101-201 will be presented at the upcoming annual meeting of the European Association for the Study of the Liver, or the 50th International Liver Congress 2015, taking place in Vienna April 22-26.

16 Apr 2015

Researchers find that cancer gene require copper to promote tumor growth

Drugs used to block copper absorption for a rare genetic condition may find an additional use as a treatment for certain types of cancer, researchers at Duke Medicine report.

10 Apr 2014

NAFLD is an independent predictor of cardiovascular risk

A study presented today at the International Liver CongressTM 2013 - which evaluated the relationship between non-alcoholic fatty liver disease (NAFLD), early predictors of atherosclerosis and the 10-year Framingham risk score (FRS) - showed that NAFLD increases the risk of early atherosclerotic lesions independent of established cardiovascular (CV) risk factors.

26 Apr 2013

Study confirms D-penicillamine and trientine effective against Wilson disease

Results from the first ever European-wide retrospective analysis presented today at the International Liver CongressTM have shown both D-penicillamine and trientine continue to be effective treatments, providing positive survival rates in patients with Wilson disease free from a liver transplant.

1 Apr 2011

Life Technologies announces winners of European Ion Torrent PGM Sequencer Grants Program

Life Technologies Corporation, today announced Dr. Angel Carracedo and Dr. Mark Pallen as the winners of the European Ion Torrent Personal Genome Machine (PGM™) Sequencer Grants Program.

19 Feb 2011

FDA extends review on Acetadote for non-acetaminophen acute liver failure

Cumberland Pharmaceuticals Inc. today announced the U.S. Food and Drug Administration (FDA) has extended its review of the supplemental new drug application (sNDA) for the use of Acetadote® (acetylcysteine) Injection in patients with non-acetaminophen acute liver failure.

21 Aug 2010

Liver biopsy with hepatic copper quantification every 3 years needs to be considered for WD patients

As a result of the rarity of Wilson disease (WD) and the fact that liver biopsy is not performed routinely during follow-up, unless clinically indicated, the progression and timing of the liver pathology and its correlation with different anti-copper treatments or aminotransferase levels are poorly characterized. Previous studies have demonstrated the possibility of improvement of steatosis and inflammation grade, and of fibrosis stage during long-term follow-up.

12 Apr 2010

Copper sequestering drug tetrathiomolybdate shown to be effective in treating Wilson disease

The copper sequestering drug tetrathiomolybdate (TM) has been shown in studies to be effective in the treatment of Wilson disease, a disease caused by an overload of copper, and certain metastatic cancers.

27 Nov 2009

Comparison study finds no significant differences in post-transplant survival rates of NASH and ETOH groups

Researchers at the University of Miami School of Medicine compared the outcomes of cirrhotic patients who underwent liver transplants for nonalcoholic steatohepatitis (NASH) versus alcoholic liver disease (ETOH) and found no statistically significant differences in post-transplant survival rates between the NASH and ETOH groups

25 Nov 2009

Wilson disease and excess copper are focus of new NIDDK publication

Wilson disease, a rare but potentially serious condition that causes the buildup of too much copper in the body, is explained in a new fact sheet from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH).

1 Jun 2009